Latest Vaxcyte News & Updates

See the latest news and media coverage for Vaxcyte. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Vaxcyte

Clinical-stage vaccine biotechnology company

vaxcyte.com
Headquarters
San Carlos, United States
Founded year
2013
Company type
Public company
Number of employees
590–1,000
Industry
Pharmaceuticals

Last updated

Latest news about Vaxcyte

In short: Vaxcyte reported positive Phase 3 VAX-31 results, meeting all OPUS-1 primary endpoints.

Company announcements

Vaxcyte

Vaxcyte launches public offerings of stock and notes

The company raises up to $1.5 billion via equity and convertible debt for vaccine development and manufacturing.

Unlock all announcements with a

Media coverage

Markets Insider

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified...

Unlock all articles with a

Never miss news about Vaxcyte

Track Vaxcyte and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.